PIK3CA and non-small cell lung carcinoma: A phase 2 trial in NSCLC is ongoing for advanced diseases with PIK3CA mutations or amplifications [270]. Taselisib, a selective PI3K inhibitor, was evaluated in the phase 2 LUNG-MAP trial in previously treated patients with PIK3CA mutations, but this arm was closed for futility [271]. As such, given the high cutaneous toxicity, and lack of efficacy of current strategies, a greater understanding of PI3K targeting is required.